ribose
Showing 1 - 25 of 375
Heart Failure, Diastolic Trial in Kansas City (CoQ10, D-Ribose Oral Powder, Placebo pills)
Completed
- Heart Failure, Diastolic
- CoQ10
- +3 more
-
Kansas City, KansasUniversity of Kansas Medical Center
Mar 9, 2022
Ovarian Tumors, BRCA1 Protein, BRCA2 Protein Trial in Worldwide (KU-0059436 (AZD2281)(PARP inhibitor))
Active, not recruiting
- Ovarian Neoplasms
- +2 more
- KU-0059436 (AZD2281)(PARP inhibitor)
-
Brussels, Belgium
- +4 more
Dec 19, 2022
Ovarian Cancer Recurrent Trial in Birmingham (M4344+Niraparib)
Not yet recruiting
- Ovarian Cancer Recurrent
-
Birmingham, AlabamaUniversity of Alabama at Birmingham
Jan 5, 2023
Sarcoma,Soft Tissue, Brachytherapy, Poly(ADP-ribose) Polymerase Inhibitors Trial in Guangzhou (Fluzoparib, Radioactive particle
Recruiting
- Sarcoma,Soft Tissue
- +2 more
- Fluzoparib
- Radioactive particle implantation
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
May 30, 2023
Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer Trial in Guangzhou (Fluzoparib
Not yet recruiting
- Ovarian Cancer
- +4 more
- Fluzoparib Capsules
- Bevacizumab
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Cetntre
Sep 25, 2023
NSCLC, EGF-R Positive NSCLC Trial in Wuxi (Parimparib, Chemotherapy drug, Targeted Therapy Agent)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- EGF-R Positive Non-Small Cell Lung Cancer
- Parimparib
- +2 more
-
Wuxi, Jiangsu, ChinaAffiliated Hospital of Jiangnan University
Jan 30, 2023
HRD and Resistance to PAPPi in EOC Patients
Recruiting
- Epithelial Ovarian Cancer
- +6 more
- Testing of homologous recombination deficiency
-
Beijing, Beijing, ChinaLei Li
Mar 26, 2022
Acute Myeloid Leukemia Trial in Baltimore (Decitabine, talazoparib)
Active, not recruiting
- Acute Myeloid Leukemia
-
Baltimore, MarylandUniversity of Maryland Greenebaum Comprehensive Cancer Center
May 31, 2022
Prostate Cancer Trial in Philadelphia ([18F]FluorThanatrace, Poly(ADP Ribose) Polymerase 1)
Active, not recruiting
- Prostate Cancer
- [18F]FluorThanatrace
- Poly(ADP Ribose) Polymerase 1
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
May 12, 2022
Homologous Recombination Deficiency in Chinese Ovarian Cancer
Not yet recruiting
- Ovarian Cancer
- +2 more
- PARP inhibitor
-
Nanjing, Jiangsu, ChinaXiaoxiang Chen, MD,PhD
Sep 4, 2021
Healthy Trial in Lillehammer (Glucose)
Completed
- Healthy
- Glucose
-
Lillehammer, NorwayInland Norway University of Applied Sciences
Feb 3, 2021
Recurrent Glioma, Recurrent Glioblastoma, Poly ADP Ribose Polymerase (PARP) Inhibitor Trial in Hong Kong (Talazoparib)
Recruiting
- Recurrent Glioma
- +4 more
-
Hong Kong, Hong KongDepartment of Clinical Oncology
Aug 19, 2021
Advanced Solid Tumors Trial in United States (KSQ-4279, KSQ-4279 will be combined in separate cohorts, including combination
Recruiting
- Advanced Solid Tumors
- KSQ-4279
- KSQ-4279 will be combined in separate cohorts, including combination with an oral PARPi (poly adenosine diphosphate-ribose polymerase inhibitor)
-
Boston, Massachusetts
- +4 more
Apr 5, 2022
Fibromyalgia, CFS Trial in Kailua (Smart Energy System)
Unknown status
- Fibromyalgia
- CFS
- Smart Energy System
-
Kailua, HawaiiKona Research Center
Oct 20, 2020
Tumors, Breast Tumors Trial in Japan (talazoparib)
Active, not recruiting
- Neoplasms
- Breast Neoplasms
-
Nagoya, Aichi, Japan
- +7 more
Dec 20, 2021
Alzheimers, Dementia Trial in Kailua (d-ribose)
Terminated
- Alzheimers
- Dementia
- d-ribose
-
Kailua, HawaiiPAN
May 6, 2020
Healthy Trial in Exeter (Low nucleotide, High nucleotide, High nucletide + Ribose)
Completed
- Healthy
- Low nucleotide
- +2 more
-
Exeter, Devon, United KingdomUniversity of Exeter - St Luke's Campus
Mar 25, 2020
Metastatic Malignant Solid Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma Trial in United States
Active, not recruiting
- Metastatic Malignant Solid Neoplasm
- +4 more
- Laboratory Biomarker Analysis
- +4 more
-
Phoenix, Arizona
- +14 more
Sep 1, 2022
Advanced Malignant Solid Tumor, Clinical Stage III Gastroesophageal Junction Adenocarcinoma, Clinical Stage IV Gastroesophageal
Recruiting
- Advanced Malignant Solid Neoplasm
- +28 more
- Trifluridine and Tipiracil Hydrochloride
- Talazoparib Tosylate
-
Buffalo, New YorkRoswell Park Cancer Institute
Mar 2, 2022
Breast Tumors, Triple-Negative, Breast Tumor Malignant Female, Radiotherapy Side Effect Trial in Paris (Olaparib, Radiation
Active, not recruiting
- Breast Neoplasms, Triple-Negative
- +2 more
- Olaparib
- Radiation therapy
-
Paris, FranceInstitut Curie
Oct 23, 2020